Data Partner

Medical Research Collaborative, LLC ("MRC") is pleased to offer the following Data Partner consultation service to institutional or other accredited investors.

Data Partners will benefit from exclusive access to MRC's analytics, including comprehensive research reports on targeted biotechnology and pharmaceutical companies identified as possessing outsized return-for-the-risk value. Both long- and short-plays are covered, with a bias towards long-plays as predominant. However, before identifying a play as possessing intrinsic upside value, MRC probes its prospects aggressively, seeking to refute its bullish investment thesis first. Only after highly critical assessment, and only if the target company has passed all tests (e.g., competitive edge and sustainability in future indication(s)/class landscape(s); meaningful differentiation of asset(s); strong management team with history of success at other companies; has one or more compelling X-factors the market is discrediting/misunderstanding, in particular misappropriated odds of successful outcome to clinical trials or drug launch; ease of access to capital markets with well-structured raises/ATM facilities; M&A potential; etc.), do we then consider it well-vetted and investible, with the potential upside price targets of its stock as reliable or even understated.

Our goal is to locate and extract value in the healthcare sector wherever we may find it. And in one sense, a bearish report can save a firm significant AUM by identifying risks it may not have considered in a given equity, and possibly gone long its stock otherwise. "A penny saved is a penny earned"and nowhere is that more true than in the world of investing, where every dollar saved is another that may be used to obtain ROI. 

MRC's valuation model identifies high "expected value" (ExV) opportunities. ExV may be derived by calculating the upside and downside potential of a given stock, and then using the odds of either occurring as a determinant of positive or negative value. The ExV is expressed as a percentage, which over many runs will equate with the ROI. Entering high-ExV trades/investments will result in significant ROI over the medium-to-long termbut it is imperative that the odds of either outcome and the upside/downside potential is ascertained as accurately as possible. That is what separates market outperformance from underperformance, and what makes MRC's informatics ultimately valuable. 

For an example of a real-time ExV scenario, please click here

As part of our commitment to Data Partners, in addition to providing comprehensive research reports on bio/pharma companies throughout the year, MRC provides updates and follow-on analyses related to all target companies covered, including:

  • Consultation on the content of any/all MRC reports 
  • Any/all patent litigation developments (PACER), and our analysis of the same
  • Detailed analyses of new clinical trial results/acquired assets
  • Notification of upcoming catalysts, especially as they draw near, with price targets ascribed to various outcomes
  • Positive and negative developments involving direct competitors
  • Planned/ongoing regulatory submissions of target companies
  • Analysis of briefing documents, should there be an AdCom, and our odds of +/- vote
  • Analysis of all SEC filings as they occur, with any deviations to prior filings identified and elaborated upon
  • Quick but thorough analysis of healthcare plays that have recently experienced a binary event, but are cycling through extreme divergent trading volume and unable to break-out further. Notable examples being CPXX at $7, AMRN at $9, AGRX at $1.20, RETA at $140, FTSV at $29.80, and KRTX at $30, all immediately after positive catalysts but just before highly significant, further price appreciation

Please Note: prior research reports are typically not available to newer Data Partners, so as to maintain fairness to those that have previously enrolled. Though one of our Bespoke Analysis packages could be put towards this use. Further, MRC reserves the right to publicly disseminate any of its research as open access, which it may do from time to time. 

For publicly divulged, time-stamped, summarized examples of our analyses, please click here(1), here(2), here(3)here(4)here(5) and here(6).

To inquire on becoming a Data Partner, including pricing options, please use our Contact Form.

Thank you.